Tag Archives: Interview

New Sackler leadership envisions training to career excellence

The beginning of this academic year has seen a shift in the leadership of the Sackler school with the retirement of both the Dean & the Associate Dean. Dr. Naomi Rosenberg’s decision to retire from her role as the Dean of Sackler after 13 years of dedicated service was received with a mixture of surprise and trepidation, which was compounded by Associate Dean Kathryn Lange’s retirement decision around the same time. The dynamic duo left large shoes to fill and the search committee spent the summer choosing candidates who would have the school and its constituents’ best interests in mind. To that end, Daniel Jay, Ph.D., a faculty member of the Developmental, Chemical & Molecular Biology department, and Daniel Volchok, Ed.D., previously the Assistant Dean for Graduate Student Life at Northeastern University, were chosen to fill the positions of the Dean and Associate Dean, respectively. Both of these individuals bring their extensive experiences to the table. Dean Jay has mentored numerous graduate students and has served as the post-doc officer for the school prior to his appointment as the Dean, and Assoc. Dean Volchok has worked with both undergraduates and graduate students across multiple disciplines that range from medical schools to business schools.

For Dean Jay, a fortuitously timed conference on graduate education solidified his commitment to throw his hat in the ring, while Assoc. Dean Volchok found that beginning his position simultaneously with a new Dean was a wonderful opportunity to build a fresh vision for Sackler from the ground up. Aside from similar serendipitous timing, Jay and Volchok also developed convergent objectives for how to keep Sackler and its associated graduate programs a competitive academic institution. Of particular interest regarding these new goals is that they grew directly out of interactions with students.

“In my interview, with the students I met with, they all talked about career,” Volchok recalled. “It was very important to the students. It turned out they were right…career focus is part of the life here.”

Jay states that their new mission for Sackler is one of “training to career excellence”, which encourages high distinction not only at the bench for students, but also in less traditionally academic contexts, such as in the boardroom or at the news desk. “The reason for that,” Jay explained, “is that 80% of our trainees go on to careers beyond academia…and we need to train all of those individuals in addition to the small number that do go on in academia to compete, to excel, and to lead in areas of whatever their chosen career passion.”

Both Jay and Volchok believe that trainees are the key to Sackler’s success. To highlight the importance of student leadership, Jay mentions that “extracurricular programs, that didn’t exist 10 years ago, were developed by student leadership such as the GSC [Graduate Student Council], TBBC [Tufts Biomedical Business Club] and the PDA [Postdoctoral Association].” They both want to see this trend to continue as they would like students to take ownership of their career choices and approach the Dean’s office with their needs and wants to ensure their success. Jay believes that “we will be stronger and better if we are willing to change with the times to provide what students require for success.” He is also less concerned that faculty may not be on board with non-traditional career choices. He believes that most faculty are not opposed to career choices outside of academia, and he stresses that research excellence is still the first priority for any trainee at the Sackler school and will not be compromised

In his twenty years at Tufts, Jay has watched, as well as aided, the trainee community forge extracurricular programs and initiatives to fulfill these alternative training needs, despite, and more aptly because of, the shortage of accessible resources. To build upon this foundation, this fall semester the Dean’s office launched two new trial initiatives: a drug development short course, taught by alumnus Stefan Gross, and career counseling services provided by Sarah Duncan. In addition, Volchok is currently working on developing a business skills course based on his experience in Northeastern’s business school; such action speaks to the fresh perspectives he brings to Sackler through his extensive and varied educational and administrative experience. While this type of career training will remain supplemental in the short-term, they plan to eventually incorporate such training directly into the infrastructure of Sackler. This integration will run the gamut from admissions to available curriculum, such as proposed course offerings focused on business or transferable skills (eg – team building, project management, etc.), school-facilitated industry internships that are integrated into a student’s research plan, and possibly a two-year biomedical Masters program that would incorporate training in both research and non-traditional science career development.

The majority of these programs will be accessible not just for graduate students but also for Tufts postdocs as well. Jay’s role as the post-doc officer for the school has made him very much aware of the bottleneck effect of the current academic job crisis that these postdocs face. Therefore, he has stressed that programs be made open to the whole Sackler community whenever possible. He also proudly mentions the success of the PDA, which organized around 70 events last year, and affirms his faith in trainee leaders to build career-related programs. Unfortunately, industry internships will not be open to postdocs, but Jay hopes to work with industry contacts to improve that situation.

The success of these programs and the new vision, according to Jay, will be evaluated by whether “graduates have an easier time finding their first job.” He mentions that he developed this milestone after his conversations with alumni who wished they had learned particular skills before entering the job market. In these conversations, he also discussed building more formal engagement between the alumni and the school, such as the possibility of alumni acting as adjunct professors to teach aforementioned short courses and the development of a biomedical research interest group. He affirms that he has had a positive reaction from the alumni who have also expressed interest in hosting/organizing events. He also mentions that alumni would definitely be a part of the new branding strategy now that the Dean’s office has developed its new mission. As a key component to executing these varied goals, Jay and Volchok have also established and seeded a new Sackler career development fund, dedicated to financing the programming to come out of this new mission.

Jay and Volchok aim to use their first year to launch programs that would serve as “trial balloons.” The school is “small, so [it is] easy to make changes”, according to latter, and therefore, they would like to test out which programs can be expanded upon in the long term. “This year will test the viability and utility of these short courses that can be used to build upon for longer term goals, and student engagement and participation will be crucial to seeing these initiatives succeed,” Jay elaborated. This last point seems to be critical to the new administration, as “feet on the ground”, as Jay put it, will be the litmus test for whether these initiatives continue. Both seemed confident that the students will indeed engage, given how proactive the trainee community has been about this topic in the past, and are ready and willing to listen to individual feedback.

“We’re of the size that we can make sure students are successful,” Volchok observed. “We can work with individual students when we need to. Students can feel like part of the community and not just a number.”

While a small student body has organizational advantages and new approaches can be tested easily without much bureaucratic repercussions, there are also disadvantages. The current funding climate, along with the fact that Sackler is surrounded by heavyweight schools with similar programs, has led to a dwindling number of students recruited to our programs every year. In the light of such events, concerns regarding the continuity of Sackler as a successful graduate school are bound to rise. However, both Jay and Volchok believe that their new mission of a strong emphasis on career development will help Sackler stand out amongst the other schools in the area.

“I view this as our route to success…how do we define ourselves in a very competitive environment,” Jay said. “If we dedicate ourselves wholeheartedly to this mission, we would, in some ways, distinguish ourselves so that we are competitive, so that a student may choose us because they seek this path toward career excellence. We have to find a way to be relevant…I think the combination of being in Boston, of being small and mobile–if we can do it, we set the standard for the rest of the country. So that is exciting to me, and that’s making a difference, and this is why I’ve taken this job.

Besides the strong emphasis on career development, the Dean’s office’s new mission also prioritizes community building both in and outside of Tufts. Jay mentions a great advantage that Sackler has by being surrounded by Medical, Dental and Nutrition schools, and being in the same university as a Veterinary school–all opening doors to an influx of opportunities for trainees and faculty to design their studies that could result in more collaboration within the school. As an example, he cites the Clinical & Translational Science Institute (CTSI) and their intentions of working more with the Sackler Basic Science programs (CTSI currently offers drop-in hours for statistics consultation and also offers a course on biostats, both of which are open to Sackler trainees). Jay is also looking forward to hearing individual programs’ changes to curriculum based on discussions between students and faculty mentors (CMDB is offering a bioinformatics class to its students after it was brought up in the program retreat). Additionally, Jay hopes to reach out to industry as well for more collaboration on various fronts.

Jay and Volchok are also tuned in to the social needs of the community to protect its members while reaching outside of their bubble. They are both advocates of the new student club Scientists Promoting Inclusive Excellence @ Sackler (SPINES), and stressed “increased awareness of diversity and inclusion” and building a tolerant community. In an effort to increase student engagement, Volchok has revised The Goods–a weekly digest of news, opportunities and events both on and off campus–delivered to the school community. He believes that “students have a good voice here” and are great resources on how the school and its environment can be improved. Both Jay and Volchok mentioned the need for more community outreach into middle schools, both in the Chinatown communities and the African-American communities in Roxbury. They would like the students to help with organizing and mentoring in these communities.

Of course, most of these ideas are still in the very early stages. “We’re at the very beginning of all this,” Jay said with a laugh. Even so, they seem to be off to a good start, as Jay and Volchok spent their first few weeks listening to the needs of the community before shaping their mission. Jay admits “…the level of concern and frustration of career path thing is here,” an issue frequently brought up by students in the past. Jay and Volchok are committed to listening to the needs of the trainees and helping them as much they can, but they also want the students to take ownership of their own career paths by being proactive. When asked what the students can do to help the Dean’s office, Volchok expresses his eagerness to work with students to improve their experience at Sackler. “Be open and honest with us. Come and tell us when things are going well. Come and tell us when things are not going well. If you have ideas and things we can do differently, let us know.”

Contributing to the Healthcare Ecosystem through Evidence-based Investing

In an effort to continually explore the interface between science and business, Tufts Biomedical Business Club recently caught up with Dr. Zach Scheiner, an Associate at RA Capital Management, for a discussion about his experience in the healthcare investment industry.

RA Capital Management is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies. Prior to his current role at RA Capital, Zach worked as a Science Officer at the California Institute for Regenerative Medicine, where he managed a portfolio of research programs concentrated in translational neuroscience. He holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington.

RA Capital Management
Zach Scheiner, PhD

As an Associate for RA Capital, Zach’s efforts are realized through the team’s core research division, TechAtlas. This division is a scientifically trained team that maps out competitive landscapes in a continual effort to survey the landscape and identify emerging therapeutics and technologies that will reshape how physicians treat disease. The interview is edited for brevity and clarity.

 

Tell me about the career path that led you to your job. How did you become involved with RA Capital Management?

My interest in biomedical science and research began as an undergrad, when I had several summer research internships and was exposed to a few different fields of research. At the same time I had my first opportunity to teach science classes at a local high school and quickly realized that I also had a passion for teaching. After graduating, I decided to teach middle school science and math for a year (which turned into three) before returning to research and going to grad school.

I attended the Neurobiology & Behavior graduate program at The University of Washington in Seattle. My thesis work focused on the molecular basis of memory and drug addiction. Though I enjoyed my time as a graduate student, by my fourth year I began to realize that the academic career path and spending more years at the lab bench were not for me. I really enjoyed reading primary literature, planning experiments, and reviewing/analyzing data, so as I finished up graduate school I began looking at alternatives where I might be able to incorporate these interests as well as leverage my scientific background in a non-research capacity.

I found a great opportunity at the California Institute for Regenerative Medicine (CIRM) in San Francisco. CIRM funds stem cell research at institutions throughout California with the goal of advancing promising stem cell based therapies into clinical trials and ultimately to patients. I began as a science writer and quickly moved to a position managing a portfolio of translational research programs. In this position, I worked closely with funded scientists to help set milestones and success criteria, assess progress, and, however possible, facilitate success. In my six years at CIRM I learned a tremendous amount about the drug development process, gained experience reviewing and analyzing data, and developed management skills, all of which have been invaluable in my current role at RA Capital.

My move to RA Capital was the result of my wife being offered an assistant professorship at Brown University. In preparation for the move from one coast to the other I reached out to everyone in my network, including an old lab-mate I had stayed in touch with from graduate school who was now an Associate for RA Capital. I had a long-time interest in biotech investing, nurtured by my dad, and had been learning about this part of the industry in my spare time. Luckily, RA was hiring and the rest is history. For me, RA Capital was a perfect fit. I can put my communication and analytical skills from teaching, grad school and CIRM to good use and I love staying immersed in cutting-edge science while learning more about the investment side of the biotech industry.

 

What are the duties/functions/responsibilities of your job?

As an Associate with RA Capital, my primary role involves creating dendrograms (mind-maps) of specific diseases or capabilities within the healthcare industry. These comprehensive landscape maps take all the available drugs, both on the market and still in development, and put them into the context of current standard of care and unmet needs. They help our team fully appreciate and contextualize the market potential of assets and companies before making investments. Mapping out a disease landscape is a research-intensive process that involves surveying the literature, meeting with companies with assets in the space, speaking directly to physicians, attending scientific conferences, and analyzing data. The process can take several months to complete but the maps are never truly finished. Therapeutic landscapes are constantly evolving, new data are released and new licensing and acquisition deals are made. Our maps are equally dynamic and a lot of my time is spent staying up to date with the latest news and data coming out in the areas I cover.

In addition to mapping, Associates also join the investment team in diligence projects on specific investment opportunities. Our maps are a great way of contextualizing drugs and their competitors and can help our team identify potential new opportunities but it’s always critical to dig deeper before making an investment. One of the most rewarding parts of my job is seeing all the work I’ve put in researching and understanding a therapeutic space pay off with insights that are potentially investable, or that directly benefit a diligence project.

On a day-to-day basis I also survey industry news and the scientific literature not only to keep up with the science but to search for new investment opportunities that could be licensable for an RA Capital portfolio company or even form the basis for a new company. I also enjoy being involved in the recruiting process at RA and playing a small role in shaping the future of the company.

 

What is the most rewarding part about your job?

Personally, the most rewarding part of my work is knowing that we are investing in companies that are developing therapies for patients that really need them! These companies often have no marketed drugs and need capital to advance their assets through clinical trials and into the hands of patients. When I think about the work that I do, I know I am helping to identify great science, underappreciated drugs, and promising new opportunities. And I hope that by influencing where RA Capital’s dollars are invested, I’m impacting the whole healthcare ecosystem in a positive way.

 


 

What experiences best prepared you for your job?

I think all of my previous work experiences helped prepare me for RA Capital, the first of which was teaching. Communication is such an essential skill and getting an opportunity to develop this early in my career has been a huge benefit. Having controlled a classroom every day for three years definitely makes communicating with colleagues, companies and scientific experts a little easier. Effective communication is a vital part of this job.

The second experience is my time spent as a graduate student. In graduate school I learned how to rigorously analyze data, both my own and from the literature. I developed my critical thinking and analytical skills and the ability to quickly identify key questions, design key experiments, and understand the limitations of a study.

Lastly, at CIRM I learned the process of moving a drug from the lab to the market and everything in between. I also regularly participated in grant review meetings with panels of scientists, clinicians, and patient advocates. These meetings gave me the opportunity to learn what was truly important to each group. While the views and opinions would often vary between the groups, one key takeaway was that for a drug to succeed, doctors have to want to prescribe it and patients have to want to use it. My experience at CIRM taught me to evaluate drugs with the patient perspective in mind; new therapies are worthless unless patients will use them, and sometimes improvements that appear marginal can be very meaningful to patients.

 

What skills or personal characteristics do you feel contribute most to success in this industry?

Very often, investment firms require that applicants have a background in finance, an MBA, or prior experience in the industry. That is not the case at RA Capital. I wouldn’t say any particular background or degree is required, but there are certainly skills that are critical. Analytical skills, for example. The ability to rigorously analyze data and quickly get to the “meat” of primary literature or a clinical data set is invaluable. Another key skill is effective writing and communication. Much of my day is spent writing and talking. I am continuously expressing my thoughts and providing analysis and it is important to do so concisely and effectively.

In terms of personal characteristics, I would highlight skepticism. Being skeptical is a common trait among scientists due to the nature of research, but this skill is especially important when meeting with companies. Every company is trying to convince us that their assets or data are the best. Skepticism is required to separate the pitch from the quality of the science.

Humility is another important personal characteristic. To put it simply, in something as complicated as drug development, it’s easy to be wrong! There are so many variables to consider, and science changes so quickly; it’s essential to have an open mind and be humble about everything you do not know.

 

What are the biggest challenges you face as an associate for RA Capital Management?

I think the largest challenge I face is simply the pace of the industry and science itself. There is new data coming out all the time; from company press releases, new primary literature, scientific conferences—the amount of information can be overwhelming. Developing the ability to quickly assimilate and analyze new information is the biggest challenge. But it’s also one of the things I enjoy most about my job. In this field you have to enjoy constant learning and also get good at processing information quickly enough to inform an investment decision. The fast pace is challenging but exciting.

 

What are some other opportunities within RA Capital Management for scientists aside from the TechAtlas Research Division?

Most opportunities for PhD trained scientists are within our TechAtlas research team. This team is made up primarily of PhD trained scientists in either Associate or Scientific Writer positions. The Science Writers work closely with the Associates as they build the story of their map, acting as a thought partner to develop the key insights for standard of care, unmet needs, and investable opportunities for each disease. As members of the research team gain experience, they can specialize in one of several areas, including early-stage assets, strategic analysis of licensing and partnerships, and equity analysis.

 

For somebody interested in pursuing this career, what would be your advice to best prepare them?

I would highly recommend that PhD candidates supplement their education in three areas: biostatistics, clinical trials, and FDA regulatory pathways. These topics are not always emphasized or even addressed in many graduate programs. A working knowledge of biostatistics goes a long way; being able to understand statistical pitfalls and the pros and cons of different analyses is invaluable. I would also recommend becoming familiar with clinical trials: the general FDA requirements for advancing drugs into Phase 1 trials and the typical development path for new therapies in your field of interest. Few graduate students get exposed to these areas. I would strongly suggest looking beyond the specific questions of own research project to get an understanding of the broader context: the standard of care for the disease, unmet needs, and competing approaches. If your research isn’t disease or therapy focused, choose a disease of interest or imagine potential applications of your work and research those. Putting new research and data into a broad context is a lot of what we do, so the earlier you can start practicing, the better prepared you will be.